Literature DB >> 24522498

Robust methods to improve efficiency and reduce bias in estimating survival curves in randomized clinical trials.

Min Zhang1.   

Abstract

In randomized clinical trials, improving efficiency and reducing bias due to chance imbalance in covariates among groups are always of considerable interest. The two purposes are often achieved by some type of covariate adjustment. In trials involving time-to-an-event, Kaplan-Meier and Nelson-Aalen estimators are the most popular nonparametric estimation of survival curves. However, these methods do not permit direct covariate adjustment, missing the important chance of improving efficiency and reducing bias. In this article, we propose robust, covariate adjusted analogues of the Nelson-Aalen and Kaplan-Meier estimators. The method is robust in that it does not require any additional modeling assumptions and hence the resulting estimators are again nonparametric. The robustness is achieved by taking advantage of the study design, i.e., treatments are randomized. Large-sample properties of the proposed estimators are developed, which show that the improvement in efficiency is guaranteed asymptotically. Simulation studies using reasonably small sample sizes further demonstrate the efficiency gain and the ability to reduce or remove bias resulted from chance imbalance to a large degree, e.g., more than 10-fold reduction in bias is achieved. Efficiency improvement and bias reduction are also illustrated by application to a cancer clinical trial. The proposed methods may help to resolve the tension between the need to make best use of data and the unwillingness to make additional assumptions in analyzing data from clinical trials.

Entities:  

Mesh:

Year:  2014        PMID: 24522498     DOI: 10.1007/s10985-014-9291-y

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  8 in total

1.  Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.

Authors:  C M Tangen; G G Koch
Journal:  J Biopharm Stat       Date:  1999-05       Impact factor: 1.051

2.  A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials.

Authors:  Emmanuel Lesaffre; Stephen Senn
Journal:  Stat Med       Date:  2003-12-15       Impact factor: 2.373

3.  Semiparametric estimation of treatment effect in a pretest-posttest study.

Authors:  Selene Leon; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

Review 4.  Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them.

Authors:  G G Koch; C M Tangen; J W Jung; I A Amara
Journal:  Stat Med       Date:  1998 Aug 15-30       Impact factor: 2.373

5.  Covariate-adjusted non-parametric survival curve estimation.

Authors:  Honghua Jiang; James Symanowski; Yongming Qu; Xiao Ni; Yanping Wang
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

6.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems.

Authors:  Stuart J Pocock; Susan E Assmann; Laura E Enos; Linda E Kasten
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

7.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

8.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

  8 in total
  5 in total

1.  Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.

Authors:  Iván Díaz; Elizabeth Colantuoni; Daniel F Hanley; Michael Rosenblum
Journal:  Lifetime Data Anal       Date:  2018-02-28       Impact factor: 1.588

2.  Landmark estimation of survival and treatment effects in observational studies.

Authors:  Layla Parast; Beth Ann Griffin
Journal:  Lifetime Data Anal       Date:  2016-02-15       Impact factor: 1.588

3.  Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  medRxiv       Date:  2020-06-11

4.  Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes.

Authors:  David Benkeser; Iván Díaz; Alex Luedtke; Jodi Segal; Daniel Scharfstein; Michael Rosenblum
Journal:  Biometrics       Date:  2020-10-11       Impact factor: 1.701

5.  Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.

Authors:  Nicholas Williams; Michael Rosenblum; Iván Díaz
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2022-09-23       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.